dan_bradbury

Profil Institute hires former Amylin chief executive

pharmafile | November 6, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |  Amylin, profil institute 

Clinical research firm Profil Institute has appointed former Amylin chief executive Dan Bradbury to its Board of directors. 

“Dan Bradbury is a highly regarded and prominent leader in the global pharmaceutical industry. We are pleased to have a person of his business acumen and relevant experience join our Board of directors,” said Dr Marcus Hompesch, Profil’s president and chief executive.

Bradbury is a life sciences executive with over 30 years of experience and is currently managing member of BioBrit, a life sciences consulting and investment firm. Prior to that Bradbury served as Amylin Pharmaceuticals’ president and chief executive from 2007 until its acquisition by Bristol-Myers Squibb in 2012.

Advertisement

Prior to joining Amylin, Bradbury worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. 

Bradbury serves on the Board of directors of Corcept Therapeutics, Geron Corporation, Illumina, BioMed Realty, Biocon, Castle Biosciences, DiaVacs and Microdermis.

Related Content

AZ image

AstraZeneca and BMS buy Amylin for $7 billion

AstraZeneca and Bristol-Myers Squibb have struck a deal to purchase diabetes specialist Amylin in a …

Amylin withheld safety data, says FDA

The US medicines regulator says Amylin held back data relating to the safety of its …

Amylin dismisses BMS acquisition deal

Amylin Pharmaceuticals has rebuffed a $3.5 billion unsolicited takeover bid from Bristol-Myers Squibb, according to …

The Gateway to Local Adoption Series

Latest content